Literature DB >> 24436616

Determinants of left ventricular hypertrophy in hypertensive patients: identification of high-risk patients by metabolic, vascular, and inflammatory risk factors.

Maya Peer1, Mona Boaz2, Matas Zipora3, Marina Shargorodsky4.   

Abstract

Left ventricular hypertrophy (LVH) is recognized as an independent predictor of cardiovascular morbidity and mortality in hypertensive patients. Thus, it is critical to understand the mechanisms underlying the development of LVH for formulation screening and treatment strategies. This study was designed to determine the association between echographically determined LVH measures and markers of inflammation, neurohormonal activity, glomerular function, oxidative stress, insulin resistance, and vascular endothelial function. In this study, 129 hypertensive subjects were evaluated for lipids, glucose, HbA1C, insulin, homeostasis model assessment-insulin resistance, C-reactive protein (CRP), urinary microalbumin, homocysteine, aldosterone, renin, and endothelin. LVH parameters including interventricular septum thickness, posterior wall thickness (PWT), and left ventricular mass index (LVMI) were assessed echographically. Serum aldosterone levels were significantly positively associated with left ventricular mass (LVM) and marginally positively associated with LVMI and PWT. Both LVM and LVMI were significantly elevated in subjects with high versus normal serum aldosterone levels (p = 0.018 for LVM and p = 0.050 for LVMI). Serum endothelin was positively associated with LVM and LVMI. In multiple linear regression analysis, aldosterone remained a significant predictor of LVM (standardized β = 0.229, p = 0.024), and endothelin a marginally significant predictor of LVM (standardized β = 0.178, p = 0.077). Among serum lipids, high-density lipoprotein cholesterol only had a significant inverse association with LVM and PWT. Homocysteine as well as CRP were significantly positively associated with LVM and LVMI in females. This study found that aldosterone and endothelin levels are the most important independent determinants of LVH in hypertensive subjects. These markers may be useful to identify asymptomatic hypertensive subjects at risk for heart failure.

Entities:  

Keywords:  cardiovascular disease; cardiovascular risk factors; creatinine; high-sensitivity C-reactive protein; hypercholesterolemia; hypertension

Year:  2013        PMID: 24436616      PMCID: PMC3830578          DOI: 10.1055/s-0033-1348880

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  15 in total

Review 1.  Endothelins: pathophysiology and treatment implications in chronic heart failure.

Authors:  John R Teerlink
Journal:  Curr Heart Fail Rep       Date:  2005-12

2.  High-density lipoprotein cholesterol and insulin resistance are independent and additive markers of left ventricular hypertrophy in essential hypertension.

Authors:  Futoshi Anan; Hidetoshi Yonemochi; Takayuki Masaki; Naohiko Takahashi; Naoya Fukunaga; Yasushi Teshima; Tetsu Iwao; Koji Kaneda; Nobuoki Eshima; Tetsunori Saikawa; Hironobu Yoshimatsu
Journal:  Hypertens Res       Date:  2007-02       Impact factor: 3.872

3.  Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling.

Authors:  C I Johnston
Journal:  Hypertension       Date:  1994-02       Impact factor: 10.190

4.  Neurohormonal activity and left ventricular geometry in patients with essential arterial hypertension.

Authors:  M W Muscholl; H Schunkert; F Muders; D Elsner; B Kuch; H W Hense; G A Riegger
Journal:  Am Heart J       Date:  1998-01       Impact factor: 4.749

5.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.

Authors:  D Levy; R J Garrison; D D Savage; W B Kannel; W P Castelli
Journal:  N Engl J Med       Date:  1990-05-31       Impact factor: 91.245

6.  Influence of plasma aldosterone on left ventricular geometry and diastolic function in treated essential hypertension.

Authors:  Yoshio Iwashima; Takeshi Horio; Setsuko Kuroda; Shuichi Takishita; Yuhei Kawano
Journal:  Hypertens Res       Date:  2002-01       Impact factor: 3.872

7.  Effect of insulin resistance on left ventricular hypertrophy and dysfunction in essential hypertension.

Authors:  K Watanabe; M Sekiya; T Tsuruoka; J Funada; H Kameoka
Journal:  J Hypertens       Date:  1999-08       Impact factor: 4.844

8.  Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure.

Authors:  M Hülsmann; B Stanek; B Frey; B Sturm; D Putz; T Kos; R Berger; W Woloszczuk; D Putz; T Kos; R Berger; W Woloszczuk; G Maurer; R Pacher
Journal:  J Am Coll Cardiol       Date:  1998-11-15       Impact factor: 24.094

9.  Relations of biomarkers representing distinct biological pathways to left ventricular geometry.

Authors:  Raghava S Velagaleti; Philimon Gona; Daniel Levy; Jayashri Aragam; Martin G Larson; Geoffrey H Tofler; Wolfgang Lieb; Thomas J Wang; Emelia J Benjamin; Ramachandran S Vasan
Journal:  Circulation       Date:  2008-11-10       Impact factor: 29.690

10.  The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT.

Authors:  Roberto Latini; Serge Masson; Inder Anand; Monica Salio; Allen Hester; Dianne Judd; Simona Barlera; Aldo P Maggioni; Gianni Tognoni; Jay N Cohn
Journal:  Eur Heart J       Date:  2004-02       Impact factor: 29.983

View more
  8 in total

1.  Procalcitonin and Pentraxin-3: Current biomarkers in inflammation in white coat hypertension.

Authors:  H Yavuzer; M Cengiz; S Yavuzer; M Rıza Altıparmak; B Korkmazer; H Balci; A L Yaldıran; H Uzun
Journal:  J Hum Hypertens       Date:  2015-06-04       Impact factor: 3.012

2.  Influence of hyperhomocysteinemia on left ventricular diastolic function in Chinese patients with hypertension.

Authors:  L Ruhui; J Jinfa; X Jiahong; M Wenlin
Journal:  Herz       Date:  2014-05-28       Impact factor: 1.443

3.  Correlation between Subclinical Heart Disease and Cardiovascular Risk Profiles in an Urban Emergency Department Population with Elevated Blood Pressures: A Pilot Study.

Authors:  Heather M Prendergast; Joseph Colla; Neal Patel; Marina Del Rios; Jared Marcucci; Ryan Scholz; Patience Ngwang; Katherine Cappitelli; Martha Daviglus; Samuel Dudley
Journal:  J Emerg Med       Date:  2015-03-20       Impact factor: 1.484

4.  Intermedin1-53 Protects Against Myocardial Fibrosis by Inhibiting Endoplasmic Reticulum Stress and Inflammation Induced by Homocysteine in Apolipoprotein E-Deficient Mice.

Authors:  Jin-Sheng Zhang; Yue-Long Hou; Wei-Wei Lu; Xian-Qiang Ni; Fan Lin; Yan-Rong Yu; Chao-Shu Tang; Yong-Fen Qi
Journal:  J Atheroscler Thromb       Date:  2016-04-06       Impact factor: 4.928

5.  Impact of the left ventricular mass index on the outcomes of severe aortic stenosis.

Authors:  Eri Minamino-Muta; Takao Kato; Takeshi Morimoto; Tomohiko Taniguchi; Moriaki Inoko; Tetsuya Haruna; Toshiaki Izumi; Shoichi Miyamoto; Eisaku Nakane; Kenichi Sasaki; Moritoshi Funasako; Koji Ueyama; Shinichi Shirai; Takeshi Kitai; Chisato Izumi; Kazuya Nagao; Tsukasa Inada; Eiji Tada; Akihiro Komasa; Katsuhisa Ishii; Naritatsu Saito; Ryuzo Sakata; Kenji Minatoya; Takeshi Kimura
Journal:  Heart       Date:  2017-07-06       Impact factor: 5.994

6.  Hyperhomocysteinemia accompany with metabolic syndrome increase the risk of left ventricular hypertrophy in rural Chinese.

Authors:  Shasha Yu; Yintao Chen; Hongmei Yang; Xiaofan Guo; Liqiang Zheng; Yingxian Sun
Journal:  BMC Cardiovasc Disord       Date:  2020-02-03       Impact factor: 2.298

7.  Is the Increased Septal Perfusion the Signal of Asymmetrical Septal Hypertrophy?

Authors:  Semra Ozdemir; Yusuf Ziya Tan; Emine Gazi
Journal:  World J Nucl Med       Date:  2016-09

8.  Association between sleep duration and cardiac structure in youths at risk for metabolic syndrome.

Authors:  Dan Feng; Jihui Zhang; Junling Fu; Heng Wu; Yonghui Wang; Lujiao Li; Yanglu Zhao; Ming Li; Shan Gao
Journal:  Sci Rep       Date:  2016-12-14       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.